Litcius/Paper detail

Guselkumab for hidradenitis suppurativa in a patient with concomitant Crohn’s disease: Report and systematic literature review of effectiveness and safety

Astrid‐Helene Ravn Jørgensen, Jesper Grønlund Holm, Simon Francis Thomsen

2020Clinical Case Reports25 citationsDOIOpen Access PDF

Abstract

Guselkumab appears to be safe and effective in the treatment of patients with HS, who do not respond to adalimumab and other systemic therapies. Guselkumab can be used in patients with comorbid Crohn's disease.

Topics & Concepts

MedicineHidradenitis suppurativaCrohn's diseaseAdalimumabDermatologyDiseaseConcomitantIntensive care medicineSurgeryInternal medicineHidradenitis Suppurativa and TreatmentsMicroscopic ColitisAutoimmune and Inflammatory Disorders
Guselkumab for hidradenitis suppurativa in a patient with concomitant Crohn’s disease: Report and systematic literature review of effectiveness and safety | Litcius